The goal of this clinical trial is to evaluate the efficacy of a topical peptide-based formulation containing Acetyl Hexapeptide-37 in promoting skin barrier recovery after controlled disruption in healthy adult participants.
The main questions it aims to answer are:
* Does the peptide cream speed up the recovery of the skin barrier after it has been slightly damaged with tape-stripping method? * How does the peptide cream compare to a placebo (a cream with no active ingredient) in improving skin hydration and reducing redness?
Researchers will compare the peptide cream to a placebo to assess its effects on skin barrier recovery
Participants will:
* Undergo controlled disruption of the skin barrier on the volar forearm using the tape-stripping method. * One forearm will receive the peptide-based cream containing Acetyl Hexapeptide-37, while the other (contralateral) forearm will receive a placebo formulation. * Attend scheduled visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema
healthy volunteers who gave written informed consent
skin disease
skin damage on measurement sites
use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial
use of emollients three days prior the inclusion in the trial